Capsida Biotherapeutics Halts CAP-002 Gene Therapy Trial Following Patient Death

Sep 12, 2025 19:42 CST Updated 19:42

Capsida Biotherapeutics

Targeted Gene Therapy Developer

Abstract:Capsida Biotherapeutics recently announced a patient death in the clinical trial of its investigational gene therapy, CAP-002. The company has not yet determined the cause of death, and has voluntarily paused the trial and reported to the U.S. Food and Drug Administration (FDA), while urgently launching an investigation. This incident has once again drawn industry attention to the safety of gene therapies, and this year, there have been multiple reports of deaths related to clinical trials in the pharmaceutical sector.

1. Trial Halted: A "Devastating" Death

On Thursday local time, Capsida stated in a statement that a patient receiving CAP-002 treatment had unfortunately passed away, describing this development as "devastating." The specific cause of the patient's death has not yet been disclosed. Capsida stated that it is "urgently collecting information and seeking answers," and promised to release more details after completing the evaluation, including the cause of death and the follow-up plans for the CAP-002 program.

It is reported that the patient suffered from STXBP1-related epileptic encephalopathy, a rare neurological disorder. CAP-002 is a gene therapy specifically developed for this condition. Following the death incident, Capsida Biotherapeutics Inc. voluntarily paused the related research and promptly informed the FDA of the situation.

"We extend our deepest condolences to the family of the patient, and the entire (patient) community is grieving this loss," Capsida said in the statement. Meanwhile, the STXBP1 Foundation, led by parents of patients, also stated that it is maintaining "close contact" with Capsida and researchers, and will "share verified updates" as the formal safety review progresses.

2. CAP-002 and STXBP1: The Battle Between Therapy and Disease

STXBP1 is a molecule that plays a critical role in cellular communication within the central nervous system, and its dysfunction can lead to developmental epileptic encephalopathy. Patients typically present with early-onset epilepsy, developmental delays, intellectual disabilities, and an elevated risk of sudden death. Currently, there are no curative therapies available for such conditions, representing a significant unmet clinical need.

As a potential breakthrough therapy, CAP-002 is administered intravenously to continuously deliver a stable supply of STXBP1 protein to the brain. Capsida Biotherapeutics' official website has emphasized that this therapy offers "superior safety" compared to other gene therapies because it does not target "non-therapeutic organs." Previously, CAP-002 received Fast Track designation and Orphan Drug designation from the FDA, raising high expectations.

However, this death incident undoubtedly casts a shadow over this "hope therapy." Industry insiders point out that although gene therapy brings new possibilities to patients with rare diseases, its mechanism of action is complex, and its long-term safety still requires more data for verification.

3. Industry Concerns: Multiple Fatal Incidents This Year Sound the Alarm

In fact, the case of Capsida Biotherapeutics is not an isolated one. Since the beginning of this year, the pharmaceutical industry has repeatedly reported deaths related to clinical trials, sparking widespread discussions about treatment safety.

The most attention has been on Sarepta Therapeutics, whose gene therapy has seen a cumulative total of three deaths, including two cases related to the Duchenne muscular dystrophy treatment drug Elevidys and one case involving a limb-girdle muscular dystrophy investigational therapy.

In early August, Allogene Therapeutics announced the termination of the development of ALLO-647, a monoclonal antibody used for lymphodepletion in CAR-T therapy clinical trials, following a patient's death. A few days later, CytomX also reported a death case in the early trials of its investigational antibody-drug conjugate for colorectal cancer. Additionally, Agios Pharmaceuticals disclosed that in July, three patients treated with its approved anemia drug Pyrukynd had died.

A series of events show that the safety risks in clinical trials are becoming a challenge that the pharmaceuticals industry can no longer ignore, especially in cutting-edge fields like gene therapy. How to balance innovation with safety remains a proposition that companies and regulatory agencies need to continuously explore.

Reference Source:https://www.biospace.com/drug-development/capsida-reports-patient-death-in-gene-therapy-trial

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Bright

All reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reproduced can contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the author and not this site.